… strategy to prevent or delay the onset of levodopa-induced dyskinesia in early-onset Parkinson's patients is to treat … symptoms of both Parkinson's disease and levodopa-induced dyskinesia. Our project investigates the possible use of D3 … selective drugs to delay or attenuate levodopa-induced dyskinesia. The goal is to determine if our novel D3 …

… Objective/Rationale: Dyskinesias, or involuntary jerking movements, are … of several new treatment strategies. However, because dyskinesias are cause various degrees of difficulty for … and caregivers differently than by doctors, the rating of dyskinesias remains a scientific challenge. This program …

… in the brain — for alleviation of involuntary movements, dyskinesias, in Parkinson's disease (PD) patients, who can experience dyskinesia as a side effect of their levodopa medication. … patients. Researchers have shown that the abnormal dyskinesia-inducing dopamine release can be effectively …

… Inhibition for the Treatment of Levodopa-induced Dyskinesia Study Rationale: Neurosteroids are substances … 5 alpha reductase (5AR) dampens involuntary movement, or dyskinesia, in models of Parkinson’s that only affects one … is responsible for the observed protection from dyskinesia. They found that inhibiting this enzyme results …

… is beset by abnormal involuntary movements, also known as dyskinesias. Research evidence indicates that aberrant … neurons contributes significantly to the expression of dyskinesias. Studies in this project will evaluate the … receptors and blockade of 5-HT2A receptors in reducing dyskinesias while maintaining L-DOPA efficacy. Project …

… of dyskinesias is based on our studies, which show that nicotine reduces levodopa-induced abnormal involuntary … evaluate the antidyskinetic potential of nicotinic drugs. Nicotine most likely exerts its effects by interacting with nAChRs. However, nicotine activates all nAChRs in the peripheral and central …